Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents

Catheterization and Cardiovascular Interventions

Volumn 78, Issue 2, 2011, Pages 161-166

  Kufner, Sebastian ^a   Massberg, Steffen ^a   Dommasch, Michael ^a   Byrne, Robert A ^a   Tiroch, Klaus ^a   Ranftl, Sabine ^a   Fusaro, Massimiliano ^a   Schömig, Albert ^a   Kastrati, Adnan ^a   Mehilli, Julinda ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

angiography; coronary; coronary flow; percutaneous coronary intervention

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BIODEGRADABLE POLYMER STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERMANENT POLYMER STENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYMERS; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960726525     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22823     Document Type: Article

References (20)

1. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-342. (Pubitemid 352001347)
2. Byrne RA, Joner M, Kastrati A,. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol 2009; 57: 567-584.
3. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510. (Pubitemid 46986103)
4. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202. (Pubitemid 43929240)
5. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009; 2: 291-299.
6. Byrne RA, Sarafoff N, Kastrati A, Schomig A,. Drug-eluting stents in percutaneous coronary intervention: A benefit-risk assessment. Drug Saf 2009; 32: 749-770.
7. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009; 30: 2441-2449.
8. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008; 372: 1163-1173.
9. Hausleiter J, Kastrati A, Wessely R, et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 2005; 26: 1475-1481. (Pubitemid 41373487)
10. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006; 113: 273-279.
11. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005; 25: 748-753. (Pubitemid 40463864)
12. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 1999; 100: 1872-1878. (Pubitemid 29511140)
13. Mehilli J, Byrne RA, Wieczorek A, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008; 29: 1975-1982.
14. Popma JJ, Leon MB, Moses JW, et al. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 2004; 110: 3773-3780. (Pubitemid 40023975)
15. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670. (Pubitemid 41175674)
16. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780. (Pubitemid 34586912)
17. Han Y, Jing Q, Xu B, et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009; 2: 303-309.
18. Byrne RA, Kufner S, Tiroch K, et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009; 95: 1489-1494.
19. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009; 119: 680-686.
20. Räber MT, Wandel S, Wigger M, Wohlwend L, Cook S, Wenaweser P, Seiler C, Eberli F, Lüscher T, Meier B, Jüni P, Windecker S,. SIRTAX-LATE: Five-year clinical and angiographic follow-up from a prospective randomized trial of sirolimus-eluting and paclitaxel-eluting stents. TCT. 2009. Available at: http://www.tctmd.com/show.aspx?id=84110. Accessed May 3, 2010.